Bifogade filer
2curex Q4 Report UK 2022 6korrektur
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2cureX AB (“2cureX”) hereby publishes the interim report for the fourth quarter and full year of 2022. The interim report is available as an attached document as well as on the company’s website (https://www.2curex.com). A short summary of the report follows below.
CEO Fernando Andreu comments:
“We finished a very successful 2022 and are proud to look back at a year where we met our goal of having IndiTreat present in 20 countries, with a total population of approximately 385M people. This - together with the expansion of our product portfolio - has considerably advanced our lead in the race for the Functional Drug Sensitivity Testing (f-DST) market.
The fourth quarter of 2022 was our strongest quarter to date, and in this quarter we enrolled as many as 9 additional hospitals to the IGNITE program compared to our revised goal of 5 hospitals. Once again we received reaffirmation that our IGNITE program is a good path to expose the benefits of IndiTreat to potential customers and we will continue our efforts on driving this forward.
Building on the positive developments of 2022 we have set ambitious goals for 2023, where we will focus our efforts and activities on penetrating the incipient European market as well as pushing forward on expanding the adoption of the f-DST technology.”
FINANCIAL HIGHLIGHTS
The financial development is in line with our plans and expectations, and with a cash position of SEK 45 MSEK at the end of 2022, our capital resources can support the current activities and growth plans.”
Full year of 2022 (2022-01-01 until 2022-12-31) – the group
Net turnover for the period was 90 KSEK (0 KSEK).
Other operating income was 3 279 KSEK (7 391 KSEK)
The result before tax was -29 770 KSEK (-22 479 KSEK)
The result per share* was -1.69 SEK (-1.15 SEK)
The solidity** was 90 % (94 %).
The cash and bank were 44 894 KSEK (72 942 KSEK).
*Earnings per share: Profit for the period divided by the average number of shares. Average number of shares in 2022: 17 580 961 shares. Total number of shares in 2cureX AB on December 31st, 2022: 17 602 916 shares.
**Equity ratio: Shareholder’s equity divided by total capital.
Significant events during the fourth quarter 2022
October:
2cureX celebrates co-inventor of patents awarded Nobel Prize in Chemistry
Independent market survey shows great demand for 2cureX product portfolio
November:
2cureX hosted a deep dive session of its operational and commercial strategy
2curex discloses status of 2022 plans, goals for 2023 and its estimates of potential market development in the coming years
2cureX publishes interim report for the third quarter 2022 and presents in live webcast
December:
2curex announces reaching the 2022 geographic rollout goal of 20 countries
Significant events after the period
January:
2curex announces final results regarding 2022 goals
2curex sends notice to attend the extraordinary general meeting for new board member
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com
Kenneth Graabek Johansen, Chief Financial Officer
E-mail: kgj@2curex.com
Telephone: +45 2349 0227
www.2curex.com